Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06461897 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
A Phase 3 study of Atopic Dermatitis, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 675
- Enrollment target
- 20
- Study locations
NCT06461897 is a Phase 3 study of Atopic Dermatitis that is actively recruiting participants, run by AbbVie. The registered enrollment target is 675 participants, above the 605-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (12% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06461897, a Phase 3 study of Atopic Dermatitis, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 675 participants
- Enrollment target
- 20
- Study locations
Study Summary
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in pediatric participants with moderate to severe AD who are candidates for systemic therapy. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for treating AD patients aged 12 or older. Participants will receive upadacitinib (given as daily dose) or dupilumab (given at label indicated dose every 2 or 4 weeks). Participants will be stratified depending on disease severity, age and response to previous treatment. There is 1 in 5 chance for participants to receive dupilumab during the randomized cohort. Approximately 675 participants aged 2 to less than 12 years of age will be enrolled in this study at approximately 150 sites worldwide. The study population (As defined by participants age or prior treatment) to be enrolled in the study is dependent on local regulatory requirement and/or agreement. Participants will receive upadacitinib oral tablets once daily (or oral solution twice a day) for 160 weeks, or dupilumab as per its label for 52 weeks, and followed for 30 days after the last dose of upadacitinib and at least 12 weeks after the last dose of dupilumab. There may be higher treatment burden for participants in this trial compared to their standard of care . Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by clinical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG Dupilumab
- DRUG Upadacitinib
Study Locations (20)
Florida
- Clearlyderm Dermatology - West Boca /ID# 266323 - Boca Raton
- Pediatric Skin Research /ID# 266308 - Coral Gables
- Neoclinical Research - Hialeah /ID# 269694 - Hialeah
California
- Stanford University School of Medicine - Palo Alto /ID# 269622 - Palo Alto
- Integrative Skin Science and Research /ID# 265108 - Sacramento
Georgia
- Cleaver Medical Group Dermatology /ID# 265099 - Dawsonville
- Aeroallergy Research Laboratory /ID# 267247 - Savannah
Illinois
- Northwestern University Feinberg School of Medicine /ID# 265117 - Chicago
- Sneeze Wheeze & Itch Associates /ID# 267238 - Normal
Maryland
- Maryland Allergy & Asthma Center /ID# 268032 - Lanham
- DermAssociates - Rockville /ID# 266457 - Rockville
Ohio
- DOCS Clinical Research - Canal Winchester /ID# 268271 - Canal Winchester
- Wright State Physicians Health Center /ID# 268841 - Fairborn
Arkansas
- Applied Research Center Of Arkansas /ID# 268547 - Little Rock
Idaho
- Treasure Valley Medical Research /ID# 266838 - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 675 participants |
| Start Date | 2024-08-19 |
| Est. Completion | 2030-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06461897
The ClinicalTrials.gov registry entry for NCT06461897 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 675 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 605-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (12% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Dupilumab is the first listed.
NCT06461897 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06461897 about?
NCT06461897 is a clinical study titled "A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis". Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilu...
What is the current status of trial NCT06461897?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 675 participants. The study started on 2024-08-19. Estimated completion is 2030-07.
What conditions does trial NCT06461897 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06461897?
The interventions under investigation include: Dupilumab (DRUG), Upadacitinib (DRUG).
Who is sponsoring clinical trial NCT06461897?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06461897 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
-
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.